08:10 AM EDT, 09/09/2025 (MT Newswires) -- Emergent BioSolutions ( EBS ) said Tuesday it has won a $56 million additional order from the US government to supply ACAM2000, a vaccine for smallpox and Mpox.

The company said that this additional order is being executed through a contract modification and the deliveries are expected to begin this month.

It added that with this modification, the total projected sales for its vaccine and ancillary products is expected to be more than $120 million this year from a diverse base of customers.

Emergent BioSolutions ( EBS ) said that this contract modification is under its existing 10-year contract with the Administration for Strategic Preparedness and Response at the United States Department of Health and Human Services.

Emergent BioSolutions ( EBS ) shares were up close to 2% in recent premarket activity.